![HeartSciences MyoVista wavECG User Manual Download Page 128](http://html.mh-extra.com/html/heartsciences/myovista-wavecg/myovista-wavecg_user-manual_2114879128.webp)
119
USER MANUAL DO-LBL-06035(L)
| MyoVista® Wavelet ECG (
wav
ECG™) 12-Lead Cardiac Testing Device
The summary represents the overall
wav
ECG Analysis results as performed by the software algorithms .
MyoVista version 2 .0 software contains algorithms which perform analysis relating to the following:
• Repolarization Measures Algorithm (relaxation abnormalities associated with LV diastolic dysfunction)
Note: Future software releases may be expanded with additional algorithms for enhanced detection
of heart disease.
For patients which are not identified by the MyoVista Device as having a significantly elevated risk of relaxation
abnormalities associated with LV diastolic dysfunction, a classification of “Normal” is displayed (see Figure
E-3) . This occurs when no abnormalities associated with MyoVista Measures, Analysis and Algorithms are
identified .
Note: This is not a “rule-out” measure, but rather a measure representing a lower risk of relaxation
abnormalities associated with LV diastolic dysfunction when compared to clinical study patients whose
categorizations are “Borderline” or “Abnormal” (as well as comparing against the overall clinical study
population).
Note: The MyoVista Wavelet Analysis is independent of Glasgow Interpretive Analysis findings.
Figure E-3
For patients which are identified by the MyoVista Device as having an elevated risk of relaxation abnormalities
associated with LV diastolic dysfunction (or where a risk assessment is inconclusive), a categorization of
“Borderline” is displayed (see Figure E-4) . In this case, additional statements explaining the summary
categorization will be provided, which include a Repolarization Measures Statement and Ischemic or Structural
risk assessment statement and may also include Ventricular Indices Statement(s), if applicable . The relative-
risk measure for “Borderline” patients when compared to patients with a “Normal”
wav
ECG is provided in
Table E-1 .
Figure E-4
For patients which are identified by the MyoVista Device as having a significantly elevated risk of relaxation
abnormalities associated with LV diastolic dysfunction, a categorization of “Abnormal” is displayed (see Figure
E-5) . In this case, additional statements explaining the summary classification will be provided, which include
a Repolarization Measures Statement and Ischemic or Structural risk assessment statement and may also
include Ventricular Indices Statement(s), if applicable . The relative-risk measure for “Abnormal” patients when
compared to patients with a “Normal”
wav
ECG is provided in Table E-1 .
Figure E-5
Appendix E: MyoVista
wav
ECG Information, Measures Development and Statistical Performance